Progress in nanoparticle-based regulation of immune cells.

Ya-Nan Fan, Gui Zhao, Yue Zhang, Qian-Ni Ye, Yi-Qun Sun, Song Shen, Yang Liu, Cong-Fei Xu, Jun Wang
Author Information
  1. Ya-Nan Fan: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  2. Gui Zhao: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  3. Yue Zhang: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  4. Qian-Ni Ye: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  5. Yi-Qun Sun: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  6. Song Shen: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China.
  7. Yang Liu: Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  8. Cong-Fei Xu: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China. ORCID
  9. Jun Wang: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong Province, China. ORCID

Abstract

Immune cells are indispensable defenders of the human body, clearing exogenous pathogens and toxicities or endogenous malignant and aging cells. Immune cell dysfunction can cause an inability to recognize, react, and remove these hazards, resulting in cancers, inflammatory diseases, autoimmune diseases, and infections. Immune cells regulation has shown great promise in treating disease, and immune agonists are usually used to treat cancers and infections caused by immune suppression. In contrast, immunosuppressants are used to treat inflammatory and autoimmune diseases. However, the key to maintaining health is to restore balance to the immune system, as excessive activation or inhibition of immune cells is a common complication of immunotherapy. Nanoparticles are efficient drug delivery systems widely used to deliver small molecule inhibitors, nucleic acid, and proteins. Using nanoparticles for the targeted delivery of drugs to immune cells provides opportunities to regulate immune cell function. In this review, we summarize the current progress of nanoparticle-based strategies for regulating immune function and discuss the prospects of future nanoparticle design to improve immunotherapy.

Keywords

References

  1. Blood Cancer J. 2021 Jun 23;11(6):119 [PMID: 34162832]
  2. Cell. 2017 Feb 9;168(4):707-723 [PMID: 28187290]
  3. JCI Insight. 2020 May 21;5(10): [PMID: 32434990]
  4. Biomaterials. 2018 Jul;172:92-104 [PMID: 29723758]
  5. Nat Nanotechnol. 2019 Jan;14(1):89-97 [PMID: 30531990]
  6. J Exp Med. 1996 Aug 1;184(2):465-72 [PMID: 8760800]
  7. Bioconjug Chem. 2012 Jun 20;23(6):1174-80 [PMID: 22607555]
  8. Int J Mol Sci. 2020 Oct 05;21(19): [PMID: 33027962]
  9. Eur J Pharm Sci. 2011 Dec 18;44(5):653-9 [PMID: 22064451]
  10. Nano Lett. 2020 Mar 11;20(3):1578-1589 [PMID: 31951421]
  11. Small. 2015 Apr;11(13):1519-25 [PMID: 25641795]
  12. Cells. 2020 Sep 15;9(9): [PMID: 32942725]
  13. Pharm Res. 2008 Jan;25(1):55-71 [PMID: 17551809]
  14. Int J Nanomedicine. 2020 Aug 13;15:6069-6084 [PMID: 32884263]
  15. ACS Nano. 2022 May 24;16(5):7168-7196 [PMID: 35446546]
  16. Curr Hematol Malig Rep. 2019 Aug;14(4):286-291 [PMID: 31187421]
  17. Cancer Cell. 2018 Apr 9;33(4):547-562 [PMID: 29634943]
  18. Nat Rev Cancer. 2019 Oct;19(10):587-602 [PMID: 31492927]
  19. ACS Nano. 2020 Oct 27;14(10):13739-13753 [PMID: 32936613]
  20. Sci Adv. 2022 Jan 14;8(2):eabj8207 [PMID: 35020437]
  21. Sci Rep. 2016 Sep 22;6:33808 [PMID: 27654170]
  22. Nanomedicine. 2017 Jan;13(1):173-182 [PMID: 27593489]
  23. Biomaterials. 2014 Jul;35(23):6098-105 [PMID: 24776487]
  24. Nat Nanotechnol. 2017 Aug;12(8):813-820 [PMID: 28416815]
  25. Mol Pharm. 2018 Jun 4;15(6):2142-2150 [PMID: 29668291]
  26. Cytotherapy. 2016 May;18(5):653-63 [PMID: 27059202]
  27. J Control Release. 2013 Jun 28;168(3):271-9 [PMID: 23562637]
  28. Nat Rev Clin Oncol. 2023 Jan;20(1):33-48 [PMID: 36307534]
  29. Immunol Rev. 1997 Apr;156:199-209 [PMID: 9176709]
  30. Nat Med. 2021 Dec;27(12):2234-2245 [PMID: 34887575]
  31. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5 [PMID: 23401509]
  32. Immunology. 2006 Jan;117(1):78-88 [PMID: 16423043]
  33. Nanoscale. 2020 Jan 7;12(1):130-144 [PMID: 31799577]
  34. Adv Mater. 2022 Apr;34(16):e2109955 [PMID: 35194836]
  35. ACS Nano. 2014 Mar 25;8(3):2252-60 [PMID: 24564881]
  36. Front Microbiol. 2022 Jan 03;12:790121 [PMID: 35046918]
  37. Nat Rev Immunol. 2019 Feb;19(2):89-103 [PMID: 30464294]
  38. Nat Biotechnol. 2018 Feb;36(2):160-169 [PMID: 29334370]
  39. J Control Release. 2016 Jun 10;231:17-28 [PMID: 26829099]
  40. AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):227-36 [PMID: 10710211]
  41. Angew Chem Int Ed Engl. 2020 Jan 27;59(5):2018-2022 [PMID: 31746532]
  42. Nature. 2016 Jun 01;534(7607):396-401 [PMID: 27281205]
  43. Magn Reson Med. 2010 May;63(5):1383-90 [PMID: 20432309]
  44. ACS Appl Mater Interfaces. 2020 Dec 23;12(51):56731-56740 [PMID: 33290037]
  45. Nat Protoc. 2022 Oct;17(10):2240-2274 [PMID: 35879454]
  46. Vaccine. 2004 Dec 16;23(5):699-708 [PMID: 15542193]
  47. Circulation. 2013 May 21;127(20):2038-46 [PMID: 23616627]
  48. Int J Nanomedicine. 2019 Nov 13;14:8875-8889 [PMID: 32009785]
  49. Cancer Lett. 2017 Feb 28;387:46-60 [PMID: 27339326]
  50. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167 [PMID: 30523282]
  51. Vaccine. 2015 May 11;33(20):2307-15 [PMID: 25842219]
  52. Nat Rev Cancer. 2020 Sep;20(9):485-503 [PMID: 32694624]
  53. Theranostics. 2018 Jan 1;8(2):533-548 [PMID: 29290825]
  54. Nature. 2017 Jul 13;547(7662):222-226 [PMID: 28678784]
  55. Nanoscale. 2016 Apr 21;8(15):8255-65 [PMID: 27031090]
  56. ACS Nano. 2017 Sep 26;11(9):9536-9549 [PMID: 28858473]
  57. Mol Ther. 2021 Nov 3;29(11):3293-3304 [PMID: 34091054]
  58. Comput Struct Biotechnol J. 2015 Nov 26;14:58-68 [PMID: 26862374]
  59. Biomaterials. 2017 Feb;118:16-26 [PMID: 27940380]
  60. Exp Biol Med (Maywood). 2016 May;241(10):1064-73 [PMID: 27229901]
  61. Biomaterials. 2005 Oct;26(29):5898-906 [PMID: 15949555]
  62. Nature. 2016 Feb 25;530(7591):434-40 [PMID: 26886799]
  63. Clin Rev Allergy Immunol. 2022 Aug;63(1):36-54 [PMID: 34417936]
  64. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1827-32 [PMID: 21245355]
  65. Biomaterials. 2019 Oct;217:119302 [PMID: 31271858]
  66. Nano Lett. 2019 Jul 10;19(7):4470-4477 [PMID: 31244234]
  67. Science. 2019 Jul 12;365(6449):162-168 [PMID: 31296767]
  68. Nat Nanotechnol. 2020 Apr;15(4):313-320 [PMID: 32251383]
  69. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515 [PMID: 32246128]
  70. Lancet. 2001 Jun 2;357(9270):1777-89 [PMID: 11403834]
  71. Biomater Sci. 2018 Sep 25;6(10):2714-2725 [PMID: 30151523]
  72. Nano Lett. 2017 Jun 14;17(6):3822-3829 [PMID: 28488871]
  73. Nano Lett. 2017 Nov 8;17(11):7045-7054 [PMID: 28994285]
  74. Nat Nanotechnol. 2017 Jul;12(7):692-700 [PMID: 28650441]
  75. Science. 2022 Jan 07;375(6576):91-96 [PMID: 34990237]
  76. Cancer Cell. 2021 Oct 11;39(10):1293-1296 [PMID: 34597591]
  77. J Immunother Cancer. 2019 Nov 15;7(1):306 [PMID: 31730012]
  78. Cell. 2022 Jan 20;185(2):250-265.e16 [PMID: 35021064]
  79. Mol Pharm. 2011 Apr 4;8(2):405-15 [PMID: 21189035]
  80. Nat Rev Immunol. 2023 May;23(5):274-288 [PMID: 36257987]
  81. J Clin Invest. 2001 Aug;108(3):415-23 [PMID: 11489935]
  82. Curr Med Chem. 2019;26(17):3009-3025 [PMID: 28782469]
  83. Biomater Sci. 2019 Nov 1;7(11):4698-4707 [PMID: 31495833]
  84. ACS Appl Mater Interfaces. 2020 Oct 28;12(43):48259-48271 [PMID: 33070614]
  85. Clin Dev Immunol. 2012;2012:925135 [PMID: 22474485]
  86. Nature. 2014 Mar 27;507(7493):519-22 [PMID: 24531764]
  87. Biomaterials. 2021 Jun;273:120784 [PMID: 33848731]
  88. J Nucl Med. 2002 Oct;43(10):1377-82 [PMID: 12368377]
  89. Cell Mol Immunol. 2019 Jan;16(1):6-18 [PMID: 29628498]
  90. Nat Commun. 2021 Mar 1;12(1):1359 [PMID: 33649336]
  91. Trends Immunol. 2021 Apr;42(4):293-311 [PMID: 33714688]
  92. Nat Rev Immunol. 2018 Feb;18(2):134-147 [PMID: 28990587]
  93. Sci Adv. 2020 Jul 03;6(27):eaba8564 [PMID: 32923587]
  94. ACS Nano. 2018 Nov 27;12(11):10843-10854 [PMID: 30346692]
  95. ACS Nano. 2017 Jun 27;11(6):5417-5429 [PMID: 28589725]
  96. Nat Biotechnol. 2021 Apr;39(4):419-421 [PMID: 33785909]
  97. Vaccine. 2007 May 16;25(20):3923-33 [PMID: 17428587]
  98. Nat Commun. 2021 May 10;12(1):2581 [PMID: 33972544]
  99. Nat Nanotechnol. 2022 May;17(5):531-540 [PMID: 35410368]
  100. Pharm Res. 2013 Jan;30(1):60-9 [PMID: 22878683]
  101. Nat Commun. 2020 Feb 28;11(1):1126 [PMID: 32111847]
  102. Nat Biomed Eng. 2020 Jun;4(6):636-648 [PMID: 32483299]
  103. Nano Lett. 2018 Aug 8;18(8):4762-4770 [PMID: 30028623]
  104. ACS Nano. 2015 Jul 28;9(7):6706-16 [PMID: 26042619]
  105. Semin Immunol. 2017 Dec;34:123-132 [PMID: 28887001]
  106. PLoS One. 2013;8(3):e60068 [PMID: 23533665]
  107. ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12182-12194 [PMID: 28338321]
  108. Vaccines (Basel). 2021 Jan 21;9(2): [PMID: 33494441]
  109. Biomaterials. 2022 Feb;281:121339 [PMID: 35078042]
  110. Nat Commun. 2016 Nov 10;7:13325 [PMID: 27830705]
  111. Nat Rev Immunol. 2020 Jun;20(6):375-388 [PMID: 32132681]
  112. Nano Lett. 2020 Jan 8;20(1):242-251 [PMID: 31790598]
  113. Int J Mol Sci. 2021 Jul 28;22(15): [PMID: 34360810]
  114. Nat Commun. 2017 Aug 30;8(1):389 [PMID: 28855514]
  115. Cell. 2015 Apr 9;161(2):201-4 [PMID: 25860604]
  116. Biomater Sci. 2018 Nov 1;6(11):3009-3018 [PMID: 30264063]
  117. Cureus. 2021 Jul 26;13(7):e16635 [PMID: 34462676]
  118. J Hematol Oncol. 2021 Mar 19;14(1):45 [PMID: 33741032]
  119. Nat Immunol. 2019 Mar;20(3):362-372 [PMID: 30742080]
  120. Allergy. 2023 Jun;78(6):1659-1663 [PMID: 36325826]
  121. Science. 2019 Feb 8;363(6427):649-654 [PMID: 30573546]
  122. Nat Rev Immunol. 2020 May;20(5):321-334 [PMID: 32005979]
  123. N Engl J Med. 2021 Aug 5;385(6):493-502 [PMID: 34215024]
  124. Cancers (Basel). 2021 Jan 08;13(2): [PMID: 33430105]
  125. J Hematol Oncol. 2021 May 31;14(1):85 [PMID: 34059100]
  126. Nat Nanotechnol. 2021 Jan;16(1):16-24 [PMID: 33199883]
  127. Nano Lett. 2018 May 9;18(5):3282-3289 [PMID: 29676151]
  128. ACS Nano. 2021 Mar 23;15(3):4636-4646 [PMID: 33651592]
  129. Immunobiology. 2013 Nov;218(11):1402-10 [PMID: 23891329]
  130. Bioconjug Chem. 2015 Dec 16;26(12):2507-13 [PMID: 26549104]
  131. Curr Opin Immunol. 2020 Dec;67:95-105 [PMID: 33242752]
  132. J Nanobiotechnology. 2021 Feb 25;19(1):59 [PMID: 33632278]
  133. Infect Immun. 1999 May;67(5):2643-8 [PMID: 10225935]
  134. Nat Mater. 2021 Mar;20(3):431-433 [PMID: 32939052]
  135. Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13785-90 [PMID: 23918395]
  136. Biomaterials. 2012 Jun;33(16):4195-203 [PMID: 22398206]
  137. Acta Biomater. 2019 Dec;100:338-351 [PMID: 31586726]
  138. Int Rev Immunol. 2010 Apr;29(2):156-83 [PMID: 20199240]
  139. ACS Appl Mater Interfaces. 2017 Jul 19;9(28):23466-23475 [PMID: 28640587]
  140. Sci Rep. 2016 Nov 28;6:37849 [PMID: 27892533]
  141. Small. 2012 Jul 23;8(14):2222-30 [PMID: 22528663]
  142. Nat Nanotechnol. 2022 Sep;17(9):1004-1014 [PMID: 35851383]
  143. Vaccine. 2013 Jun 19;31(28):2954-62 [PMID: 23623858]
  144. Immunity. 2021 Jul 13;54(7):1377-1391 [PMID: 34260886]
  145. Adv Funct Mater. 2015 Jul 15;25(27):4183-4194 [PMID: 27340392]
  146. Trends Immunol. 2007 Jun;28(6):252-9 [PMID: 17466596]
  147. Pol J Microbiol. 2015;64(1):3-13 [PMID: 26094310]
  148. Nat Mater. 2017 Apr;16(4):489-496 [PMID: 28024156]
  149. Nat Commun. 2020 Nov 27;11(1):6080 [PMID: 33247092]
  150. Adv Mater. 2020 Aug;32(33):e2002739 [PMID: 32656801]
  151. Pathol Biol (Paris). 2003 Mar;51(2):59-60 [PMID: 12801800]
  152. Nat Rev Immunol. 2002 May;2(5):309-22 [PMID: 12033737]
  153. Methods Mol Biol. 2018;1776:97-123 [PMID: 29869237]
  154. Front Immunol. 2020 May 12;11:812 [PMID: 32477340]
  155. Front Immunol. 2018 Jun 26;9:1432 [PMID: 29997617]
  156. Cell. 2019 Jun 13;177(7):1701-1713.e16 [PMID: 31155232]
  157. Mol Pharm. 2018 Sep 4;15(9):3642-3653 [PMID: 29337566]
  158. ACS Appl Mater Interfaces. 2021 Jun 30;13(25):29424-29438 [PMID: 34129318]
  159. Biomater Sci. 2018 Dec 18;7(1):113-124 [PMID: 30444251]
  160. Biomater Sci. 2020 Sep 7;8(17):4653-4664 [PMID: 32672255]
  161. Cell Rep. 2016 May 31;15(9):1986-99 [PMID: 27210756]
  162. Immunity. 2018 Feb 20;48(2):202-213 [PMID: 29466753]
  163. Nature. 2013 Jul 4;499(7456):102-6 [PMID: 23698367]
  164. Adv Sci (Weinh). 2019 Jun 21;6(17):1900101 [PMID: 31508270]
  165. Science. 2021 Jan 8;371(6525):145-153 [PMID: 33414215]
  166. Science. 2018 Mar 23;359(6382):1350-1355 [PMID: 29567705]
  167. Nat Mater. 2011 Mar;10(3):243-51 [PMID: 21336265]
  168. Nat Nanotechnol. 2018 Dec;13(12):1182-1190 [PMID: 30177807]
  169. Nat Rev Immunol. 2022 Mar;22(3):173-187 [PMID: 34230649]
  170. Nat Biotechnol. 2015 Jan;33(1):64-72 [PMID: 25485616]
  171. Nat Nanotechnol. 2017 Jul;12(7):701-710 [PMID: 28436959]
  172. Nat Immunol. 2008 May;9(5):503-10 [PMID: 18425107]
  173. Biomaterials. 2012 Aug;33(22):5584-92 [PMID: 22575830]
  174. Cancer Res. 2010 Nov 15;70(22):9053-61 [PMID: 20926399]
  175. J Am Chem Soc. 2018 Dec 5;140(48):16413-16417 [PMID: 30452238]
  176. Nat Rev Rheumatol. 2019 May;15(5):303-315 [PMID: 30967621]
  177. J Biotechnol. 2019 Dec 20;306:203-212 [PMID: 31634510]
  178. Nat Biomed Eng. 2018 Aug;2(8):589-599 [PMID: 30956894]
  179. Nanomedicine. 2021 Feb;32:102333 [PMID: 33188908]
  180. Mol Cancer. 2020 Aug 6;19(1):120 [PMID: 32762681]
  181. J Control Release. 2002 Dec 13;85(1-3):247-62 [PMID: 12480329]
  182. ACS Nano. 2019 Feb 26;13(2):1078-1096 [PMID: 30608136]
  183. Nat Rev Immunol. 2022 Apr;22(4):209-223 [PMID: 34253904]
  184. Biomaterials. 2009 Sep;30(27):4763-76 [PMID: 19540583]
  185. Nat Rev Immunol. 2019 Oct;19(10):599-613 [PMID: 31350531]
  186. Adv Mater. 2020 Jul;32(30):e2001808 [PMID: 32538494]
  187. Science. 2019 Feb 8;363(6427):584-585 [PMID: 30733404]
  188. Sci Rep. 2020 May 29;10(1):8764 [PMID: 32472093]
  189. Nat Rev Drug Discov. 2020 Apr;19(4):253-275 [PMID: 31969717]
  190. Nano Lett. 2012 Apr 11;12(4):2003-12 [PMID: 22372996]
  191. Front Immunol. 2015 Dec 21;6:642 [PMID: 26734009]
  192. Adv Mater. 2021 Jan;33(3):e2006160 [PMID: 33296121]

Word Cloud

Created with Highcharts 10.0.0immunecellsImmunecelldiseasesusedimmunotherapydeliverycancersinflammatoryautoimmuneinfectionsregulationtreatdrugfunctionnanoparticle-basednanoparticleindispensabledefendershumanbodyclearingexogenouspathogenstoxicitiesendogenousmalignantagingdysfunctioncancauseinabilityrecognizereactremovehazardsresultingshowngreatpromisetreatingdiseaseagonistsusuallycausedsuppressioncontrastimmunosuppressantsHoweverkeymaintaininghealthrestorebalancesystemexcessiveactivationinhibitioncommoncomplicationNanoparticlesefficientsystemswidelydeliversmallmoleculeinhibitorsnucleicacidproteinsUsingnanoparticlestargeteddrugsprovidesopportunitiesregulatereviewsummarizecurrentprogressstrategiesregulatingdiscussprospectsfuturedesignimproveProgressbiomaterial

Similar Articles

Cited By